Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Key Points:

• Gilead Sciences has entered into a definitive agreement to acquire Ouro Medicines, a biotech company developing T cell engager therapies for autoimmune diseases, for $1.675 billion upfront plus up to $500 million in milestone payments.
• The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager showing promising efficacy and safety in Phase 1/2 trials for autoimmune hemolytic anemia and immune thrombocytopenia, with FDA Fast Track and Orphan Drug designations.
• Gilead is negotiating a strategic collaboration with Galapagos, where Galapagos would co-fund development costs, retain Ouro's employees, and share development responsibilities, while Gilead retains global commercialization rights outside Greater China.
• OM336 aims to provide durable disease control by targeting pathogenic B cells and plasma cells, potentially enabling drug-free remission without ongoing immunosuppression, complementing Gilead’s existing inflammation and CAR-T therapy portfolios.
• The transaction is subject to customary closing conditions and regulatory approvals, with financial and legal advisors engaged by all parties; Gilead emphasizes forward-looking risks including integration challenges and regulatory uncertainties.